Background {#Sec1}
==========

Cardiovascular disease (CVD) represents the major cause of hospital admission, disability in middle-aged and older patients, and remains the leading cause of death (40%) in Germany \[[@CR1], [@CR2]\]. The burden of CVD is maintained by the high prevalence of modifiable vascular risk factors in the population including an unhealthy lifestyle \[[@CR3]\]. Several national and international guidelines describe the principles of cardiovascular prevention in people without established CVD (primary prevention) \[[@CR4]--[@CR7]\]. Most guidelines tailor their recommendations according to the estimated absolute CVD risk (e.g. by applying risk scores) including the adoption of a healthy lifestyle in low risk persons (e.g. prudent eating habits, non-smoking, avoiding obesity, regular physical activity), and uptake of drug medication in the asymptomatic high risk population \[[@CR4]\].

Previous studies reporting on the quality of adequate cardiovascular (CV) risk factor control in primary prevention were frequently based on samples derived from primary care. These studies suggested an insufficient implementation of CVD prevention strategies including management of obesity, blood pressure (BP), and lipid and glucose metabolism \[[@CR8]--[@CR15]\]. Little, however, is known about of the control of risk factors CVD in population-based samples \[[@CR16]\]. This is important as estimates originating from studies in primary care may not be representative of the general population because individuals attending a primary care physician usually have a reason to do so. Such selection and indication bias will profoundly affect prevalence estimates.

Therefore, we assessed in subjects without established CVD sampled from the general population of Germany the prevalence of CV risk factors, the frequency of inadequate risk factor control, and factors determining the accumulation of insufficiently controlled risk.

Methods {#Sec2}
=======

Study population and recruitment {#Sec3}
--------------------------------

The methodology of Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression (STAAB) Cohort Study has been published previously \[[@CR17]\]. Briefly, STAAB was initiated in Dec 2013 to determine the prevalence and natural course of the early stages of heart failure in a representative sample (*n* = 5000) of the general population of Würzburg aged 30--79 years. Participants undergo a detailed examination at the joint survey unit of the Comprehensive Heart Failure Center (CHFC) and the Institute of Clinical Epidemiology and Biometry (ICE-B) of the University of Würzburg, Germany. The current report is based on the first planned interim-analysis of STAAB including *n* = 1468 participants, who had been enrolled by April 2015 (positive response rate 32.6%) \[[@CR17]\]. We excluded *n* = 89 (6.1%) participants with established CVD defined by self-reported history of coronary artery disease (*n* = 56), peripheral artery disease (*n* = 11), stroke (*n* = 28). Hence, the current report is based on *n* = 1379 subjects.

Assessment of cardiovascular risk factors {#Sec4}
-----------------------------------------

Sociodemographic status, information on smoking and on physical activity was obtained via face-to-face interview. History of CVD and medication intake was assessed by study physicians. BP values were given as median of up to three valid measurements. Low density liproprotein (LDL) cholesterol and glycated hemoglobin levels (HbA1c) levels were measured at the day of examination at the Central Core Laboratory of the University Hospital of Würzburg.

Treatment goals for cardiovascular risk factors {#Sec5}
-----------------------------------------------

We identified the proportions of participants achieving the defined goals for risk factor control according to the most recent European Guidelines on CVD prevention in clinical practice (version 2016) \[[@CR4]\] including: target BP \<140/90 mmHg (\<140/85 mmHg in subjects with DM type 2; \<130/80 mmHg in DM type 1); target LDL cholesterol \<115 mg/dl (\<100 mg/dl in diabetics and participants at high risk \[for definition, see below\]); absence of tobacco abuse (self-reported in a structured interview); absence of overweight (body mass index ≤25 kg/m^2^); absence of diabetes mellitus (DM; no self-reported DM and HbA1c \<6.5%); adequate glycemic control in treated diabetics (HbA1c \<7.0%); and physical activity (≥150 min/week moderate activity or ≥75 min/week strenuous activity, operationalized by the IPAQ questionnaire \[[@CR18]\]). All risk factors above recommended target that were not self-reported (high BP, high LDL-cholesterol and diabetes) were defined as unreported. For the definitions of the six uncontrolled CV risk factors and their subgroups, see: Additional file [1](#MOESM1){ref-type="media"}.

Determinants of accumulation of uncontrolled risk factors {#Sec6}
---------------------------------------------------------

We identified a priori a set of covariates that were potentially related to the control of CV risk factors including: age, sex, markers of socioeconomic status (level of education and income), and marital status \[[@CR19]--[@CR22]\]. In addition, we performed a sensitivity analysis investigating if the predictors of three or more uncontrolled risk factors differed by sex.

Absolute cardiovascular risk estimation with systematic COronary risk evaluation (SCORE) {#Sec7}
----------------------------------------------------------------------------------------

To assess differences in prevalence of risk factor control across different CV risk groups, we applied the recently updated SCORE algorithm for Germany predicting 10-year risk of CV death \[[@CR23]\]; SCORE has been derived from subjects without a constellation indicating increased vascular risk (as prior CVD or DM). The SCORE equation weights the following factors: age (40--69), sex, current smoking, systolic BP, and total cholesterol. For the present analyses, our sample was categorized according to thresholds recommended by the European Society of Cardiology into "low risk" (SCORE \<1%), "moderate risk" (SCORE ≥1% and \<5%), and "high to very risk" (SCORE ≥5%) \[[@CR4], [@CR24]\].

Data analysis {#Sec8}
-------------

We calculated mean standard deviation (±SD) and median (quartiles) for continuous variables and proportions (%) for categorical variables. In univariate analyses, Fisher's exact test or χ^2^- test for categorical and binary variables, Mann-Whitney U-test for continuous variables (non-normal distributions) and Kruskal-Wallis test were used as appropriate. Accumulation of uncontrolled risk factors (RR ≥140/90 mmHg \[≥130/80 mmHg for subjects with diabetes\]; LDL cholesterol ≥115 mg/dl; tobacco abuse (self-reported); overweight \[body mass index \>25 kg/m^2^\]; DM \[HbA1c \>6.5%\] and physical inactive \[\<150 min/week moderate or \<75 min/week strenuous activity\]) was categorized by the median sum of uncontrolled risk factors in our population (0--2 vs. 3--6). We calculated odds ratios (OR) for the association of age, sex, education and marital status with accumulation of risk factors by multivariable logistic regression. *P*-values \<0.05 were considered statistically significant. Analyses were performed with IBM SPSS Statistics 23 (IBM® SPSS® Statistics Version 23).

Results {#Sec9}
=======

Characteristics of the study participants and prevalence of CV risk factors {#Sec10}
---------------------------------------------------------------------------

Characteristics of the study population and prevalence of CV risk factors by sex are displayed in Table [1](#Tab1){ref-type="table"}. Mean age was 53.1 years (SD 11.9), 52.9% were females. As compared to women, men reported a longer duration of education and a higher household income per month.  More men than women were married (*p* \<0.001), whereas more women than men were divorced ore widowed (both *p* \<0.001). Table 1Sociodemographic status and control of risk factors stratified by sexN~Total~FemaleMale*P*-value1379729 (52.9)650 (47.1)*Age group in years*0.62 30--39166 (12.0)82 (11.2)84 (12.9) 40--49417 (30.2)226 (31.0)191 (29.4) 50--59339 (24.6)185 (25.4)154 (23.7) 60--69340 (24.7)180 (24.7)160 (24.6) 70--79117 (8.5)56 (7.7)61 (9.4)*Highest education in years*\<0.001 Primary (\<10 yrs)331 (24.1)163 (22.4)168 (26.0) Secondary (10 yrs)411 (29.9)257 (35.3)154 (23.8) Tertiary (12 yrs)621 (45.2)301 (41.3)320 (49.5) Unclassified12 (0.9)7 (1.0)5 (0.8)*Marital status*\<0.001 Single337 (24.5)177 (24.3)160 (24.7) Married811 (59.0)396 (54.4)415 (64.1) Divorced157 (11.4)104 (14.3)53 (8.2) Widowed70 (5.1)51 (7.0)19 (2.9)*Household net income per month in Euro*\<0.001  \<1500168 (13.2)112 (16.9)56 (9.1) 1500 to \<2900458 (35.9)259 (20.3)199 (32.4) 2900 to \<5000421 (33.0)192 (29.0)229 (37.3)  \>5000229 (17.9)99 (15.0)130 (21.2)*BP* ^*a*^ *(mmHg)* Systolic129.0 (118.0; 142.0)123.0 (113.0; 138.0)133.5 (123.0; 144.0)\<0.001 Diastolic79.0 (72.5; 85.5)76.5 (70.5; 83.5)81.0 (75.5; 88.0)\<0.001*High BP levels* Self-reported hypertension546 (39.6)282 (38.7)264 (40.6)0.46 BP ≥140/90 mmHg433 (31.8)177 (24.7)256 (39.6)\<0.001 Unreported high BP above target156 (36.0)47 (26.6)109 (42.6)0.001 Antihypertensive medication372 (27.0)197 (27.0)175 (27.0)0.90 High BP level despite medication^e^193 (52.7)94 (48.7)99 (57.2)0.12 Diabetics treated with antihypertensive agents38 (67.9)17 (68.0)21 (67.7)0.98 High BP level despite medication^e^ in diabetics Type 12 (5.6)1 (6.7)1 (4.8)0.76 Type 216 (44.4)6 (40.0)10 (47.6)0.62Diabetes mellitus Self-reported diabetes79 (5.7)43 (5.9)36 (5.5)0.77 HbA1c \>6.5%46 (3.5)22 (3.2)24 (3.9)0.50 Unreported DM above target13 (28.3)7 (31.8)6 (25.0)0.75 Antidiabetic medication56 (4.1)25 (3.4)31 (4.8)0.20 HbA1c ≥ 7% despite antidiabetics^e^22 (44.0)9 (39.1)13 (48.1)0.52*LDL-cholesterol* ^b^ *(mg/dl)*120.0 (100.0; 146.0)117.5 (96.8; 146.0)123.0 (105.5; 146.0)\<0.01*High LDL-cholesterol levels* Self-reported hyperlipidemia488 (35.4)247 (33.9)241 (37.1)0.22 LDL-C \>115 mg/dl753 (57.6)365 (52.9)388 (62.8)\<0.001 Unreported high LDL-C levels above target408 (54.2)187 (51.2)221 (57.0)0.12 Lipid-lowering agents112 (8.1)47 (6.4)65 (10.0)0.02 High LDL-C level despite medication^e^38 (37.3)18 (42.9)20 (33.3)0.33 Lipid lowering treated diabetics22 (39.3)8 (32.0)14 (45.2)0.32 High LDL-C level despite medication^e^ in diabetics4 (21.1)2 (28.6)2 (16.7)0.84*Physically inactive*323 (30.8)180 (33.1)143 (28.2)0.08*Overweight*\<0.001 BMI^c^ (kg/m^2^)25.5 (23.0; 28.9)24.7 (21.9; 28.5)26.3 (24.2; 29.1)\<0.001 BMI \> 25 kg/m^2^751 (55.2)336 (46.7)415 (64.7)\<0.001 BMI \> 25 kg/m^2^ despite physical activity393 (54.9)162 (45.4)231 (64.3)\<0.001*Current smoking*266 (19.3)121 (16.6)145 (22.3)\<0.01*Insufficiently controlled CV risk factors* ^*d*^\<0.001 0--2639 (65.8)361 (72.3)278 (58.9) 3--6322 (23.2)138 (27.7)194 (41.1)Data are count (percent) or median (quartiles). Analyses are restricted to patients without missing values in respective variables.^a^Blood pressure^b^Low density lipoprotein- Cholesterol^c^Body mass index^d^Cardiovascular risk factors^e^Proportion addressed at participant being treated

Of all participants, 19.3% reported current smoking (Table [1](#Tab1){ref-type="table"}), with a significant preponderance in men. Overweight and high BP were significantly more present in men compared to women, as were LDL cholesterol levels. Prevalence of self-reported hypertension, hyperlipidemia and diabetes was independent from sex.

Achievement of recommended treatment goals and its determinants {#Sec11}
---------------------------------------------------------------

CV pharmacotherapy was reported in 422 individuals (30.7%), with no difference between women and men, but a significant greater proportion observed at higher age (*p* \<0.001).

Hypertension {#Sec12}
------------

In the total sample 433 participants (31.8%) had BP levels above the recommended target of 140/90 mmHg (Table [1](#Tab1){ref-type="table"}). More men were detected with higher BP levels as compared to women (39.6% vs. 24.7%, respectively; *p* \<0.001). Amongst subjects with raised BP levels, 156 (36.0%) had not been diagnosed by previous visits to a physician (women: 26.6% vs. men: 42.6%, *p* = 0.001). Amongst 372 (27.0%) subjects receiving antihypertensive medication, 193 (52.7%) did not achieve recommended BP targets (men 48.7% vs. women 57.2%, *p* = 0.12).

Diabetes mellitus {#Sec13}
-----------------

At the study visit, 46 subjects (3.5%) had an HbA1c value \>6.5%, with no sex-specific differences (*p* = 0.50), while 13 (28.3%) were diagnostically naïve. Of the 56 (4.1%) participants receiving antidiabetic medication, 22 (44.0%) did not reach the recommended target (HbA1c \<7.0%). Of 38 (67.9%) diabetic participants treated for hypertension, 16 (44.4%) subjects with DM type 2 were above the recommended BP of 140/85 mmHg, and 2 subjects (5.6%) \>130/80 mmHg for DM type 1. Of subjects treated for hyperlipidemia, 4 (21.1%) had LDL cholesterol levels \>100 mg/dl, with no differences beteen sexes.

Hyperlipidemia {#Sec14}
--------------

More than a half of the participants (57.6%) had LDL cholesterol levels equal or above the target of 115 mg/dl (men 62.8% vs. women 52.9%, *p* \<0.001). Amongst those, 408 subjects (54.2%) were unaware of this constellation; 112 participants took lipid-lowering medication, with 38 individuals (37.3%) above the recommended target despite medication.

We found the highest proportion of unreported risk factors at the age of 30--39 years for high BP levels (76.5%) and high LDL cholesterol (78.0%), and at the age of 60--69 years for HbA1c \>6.5% (43.5%).

Determinants of accumulation of uncontrolled risk factors {#Sec15}
---------------------------------------------------------

In the total sample, the median number of uncontrolled risk factors was 2 (range 0--6; quartiles 1, 3). Only a small proportion, i.e. 11.4%, was lacked any risk factor. In the multivariable model, probability for having three or more uncontrolled risk factors was associated with male sex (OR 1.94, 95%CI 1.44--2.61), lower level of education (OR for primary vs. tertiary: 2.15, 95%CI 1.48--3.11) and higher age (OR for 30--39 years vs. 70--79 years: 4.01, 95%CI 1.94--8.31; Table [2](#Tab2){ref-type="table"}). In a sensitivity analysis, no major differences became apparent between men and women regarding the predictors of 3 or more uncontrolled risk factors \[for details refer to Additional file [2](#MOESM2){ref-type="media"}\].Table 2Relative risk (odds ratio) for exhibiting 3--6 insufficiently controlled cardiovascular risk factors (referent: 0--2 risk factors)VariablesOdds ratio (95%CI)*P*-value*Sex*\<0.001 Female1 Male1.94 (1.44; 2.61)*Age group in years*\<0.001 30--391 40--491.77 (1.01; 3.09) 50--592.10 (1.18; 3.72) 60--693.26 (1.84; 5.78) 70--794.01 (1.94; 8.31)*Highest education in years*\<0.001 Tertiary1 Secondary1.35 (0.95; 1.92) Primary2.15 (1.48; 3.11)*Household net income per month in Euro\**0.27  ≥23001  \<23001.21 (0.86; 1.769)*Marital Status\**0.48 Married1 Single0.82 (0.57; 1.23) Divorced1.27 (0.78; 2.01) Widowed1.07 (0.54; 2.14)Insufficiently controlled cardiovascular risk factor: value above target, independent of patient awareness and current pharmacotherapy, adjusted for sociodemographic status.\*Odds ratio given before being removed from model

10-year risk estimation for fatal CVD by SCORE {#Sec16}
----------------------------------------------

For this analysis subjects with DM, CVD, and those younger than 40 years or older than 69 years were excluded (Fig. [1](#Fig1){ref-type="fig"}). Hence, SCORE values could be calculated in 980 subjects. Median SCORE was 1.0 (quartiles 1, 2), and subjects were categorized into low, medium, high to very high risk categories in 56.6%, 35.8%, and 7.5%, respectively (Table [3](#Tab3){ref-type="table"}).Fig. 1Sample Selection for SCORE estimation Table 3Sociodemographic status and control of cardiovascular risk factors stratified by SCOREN~Total~Total cardiovascular risk (SCORE)980\<1% (low)\
555 (56.6)≥1 to \<5% (medium)\
351 (35.8)≥5% (high to very high)\
74 (7.5)*p*-value*Gender*\<0.001 Female523 (53.4)374 (67.4)146 (41.6)3 (4.1) Male457 (46.6)181 (32.6)205 (58.4)71 (95.9)*Age in years*\<0.001 40--49377 (38.5)359 (64.7)18 (5.1)0 (0.0) 50--59308 (31.4)171 (30.8)133 (37.9)4 (5.4) 60--69295 (30.1)25 (4.5)200 (57.0)70 (94.6)*Highest education* *in* *years*0.001 Primary (\< 10 yrs)223 (22.8)96 (17.3)104 (29.7)23 (31.5) Secondary (10 yrs)319 (32.7)188 (33.9)111 (31.7)20 (27.4) Tertiary (12 yrs)426 (43.6)265 (47.8)132 (37.7)29 (39.7) unclassified9 (0.9)5 (0.9)3 (0.9)1 (1.4)*Marital status*0.13 Single208 (21.2)132 (23.8)67 (19.1)9 (12.2) Married610 (62.3)337 (60.8)219 (62.4)54 (73.0) Divorced122 (12.5)67 (12.1)47 (13.4)8 (10.8) Widowed39 (4.0)18 (3.2)18 (5.1)3 (4.1)*Net income per month in Euro*0.02  \<1500109 (12.0)48 (9.3)47 (14.5)14 (20.0) 1500 to \<2900297 (32.6)163 (31.6)111 (37.4)123 (32.9) 2900 to \<5000311 (34.1)182 (35.3)111 (34.2)18 (25.7)  \>5000194 (21.3)123 (23.8)56 (17.2)15 (21.4)*BP* ^*a*^ *(mmHg)* Systolic128.0 (118.0; 141.0)122.5 (114.5; 132.5)135.5 (124.0; 148.0)149.3 (137.8;161.9)\<0.001 Diastolic79.5 (73.0; 86.4)77.5 (71.5; 84.5)81.5 (75.0; 88.5)85.0 (80.0; 90.9)\<0.001*High BP levels* Self-reported hypertension366 (37.3)154 (27.9)173 (49.9)39 (52.7)\<0.001 BP \> 140/90 mmHg302 (30.8)90 (16.2)157 (44.7)55 (74.3)\<0.001 Antihypertensive treatment238 (24.3)85 (15.3)129 (36.8)24 (32.4)\<0.001 High BP level despite medication^d^120 (50.4)28 (32.9)70 (54.3)22 (91.7)\<0.001*LDL- Cholesterol* ^b^ *(mg/dl)*124 (104.0; 149.0)118.0 (98.0; 140.0)131.0 (111.0; 160.0)127.5 (105.8148.3)\<0.001*High LDL-C levels* Self-reported hyperlipidemia347 (35.4)145 (26.8)173 (50.4)29 (40.3)\<0.001 LDL ≥ 115 mg/dl604 (61.6)304 (54.8)251 (71.5)61 (82.4)\<0.001 Lipid-lowering agents56 (5.7)15 (2.7)31 (8.8)10 (13.5)\<0.001 High LDL-C level despite medication^d^27 (48.2)9 (60.0)14 (45.2)4 (40.0)0.54*Physically* *inactive*224 (29.5)137 (31.1)75 (28.5)12 (21.4)0.30*Overweight* BMI^c^ (kg/m^2^)25.5 (22.8; 28.8)24.7 (22.1; 28.1)26.2 (23.7; 29.4)27.5 (24.7; 29.5)\<0.001 BMI \> 25 kg/m^2^536 (55.1)260 (47.1)222 (64.0)54 (73.0)\<0.001 BMI \> 25 kg/m^2^ despite physical activity^d^294 (55.6)145 (48.3)116 (62.7)33 (75.0)\<0.001*Current smoking*201 (20.5)102 (18.4)72 (20.5)27 (36.5)0.001Data are count (percent) and median (quartiles). Analyses restricted to patients without missing values in respective variables^a^Blood pressure^b^Low density lipoprotein- Cholesterol^c^Body mass index^d^Proportion addressed at participant being treated

Participants at high risk were more likely to be male (*p* \<0.001) and of older age (p \<0.001). Reflecting the risk factors included in the SCORE calculation, those with higher risk more frequently exhibited hypertension and high LDL cholesterol levels (all i \<0.001). Lifestyles habits (overweight and smoking), educational level (*p* \<0.001) and net income per month (p = 0.02) were also associated with SCORE categories. In participants receiving antihypertensive medication, the proportion not achieving the recommended BP target rose from 16.2% in the low risk group to 74.3% in the high risk group. In participants with elevated LDL cholesterol levels, risk factors were more frequently insufficiently controlled despite medication (low risk 60.0% vs. high risk 40.0%).

Discussion {#Sec17}
==========

In this cross-sectional study from the general population without established CVD, prevalence of modifiable CV risk factors was high, and risk factors were frequently inadequately controlled (median = 2). A substantial number of individuals did not report any CV risk factor, and in a sizeable proportion of participants on guideline-recommended medication, treatment targets were not achieved. For example, over half of participants on antihypertensive medication had elevated BP levels at the interview. In about one third of participants on lipid lowering drugs, LDL cholesterol levels remained inappropriately high, and in more than 40% of patients on antidiabetic treatment DM was inadequately controlled. We also found a high proportion of adverse lifestyle factors such as insufficient physical activity or overweight and obesity. Individuals with a larger number of insufficiently controlled risk factors were more likely to be older and of male sex, and had spent less time in education.

We investigated the accumulation of cardiovascular risk factors and its determinants in a population-based sample in Germany. Previous European studies on this topic mainly recruited within the general practitioner setting or focused on individual risk factors and their control in population samples. Due to differences in study design and study population, various definitions of adequate risk factor control in national and international recommendation for cardiovascular prevention of CVD over time, and variations in study protocols, direct comparisons of our results with previous studies are limited. However, the prevalence figures of investigated cardiovascular risk factors are comparable with previous data from the population based studies in Germany \[[@CR25]--[@CR29]\].

Control of risk factors in German population-based samples {#Sec18}
----------------------------------------------------------

### Hypertension {#Sec19}

The longitudinal *DEGS1* (German Health Interview and Examination Survey for Adults) and *GNHIES98* (National Health Interview and Examination Surveys 1998) combined data of 2231 individuals, who were normotensive at baseline but developed hypertension in the course of 12 years of follow-up. This analysis also reported lower proportions of individuals receiving antihypertensive medication but not reaching treatment targets in women (41.0%) as compared to men (49.7%). However, in general, BP control in both genders was better than in our sample, and the occurrence of hypertension was related to higher age, BMI, and alcohol consumption \[[@CR30]\]. Another longitudinal German study, *KORA* (Cooperative Health Research in the Augsburg Region in South Germany), showed a similar prevalence of hypertension (49.2%) at baseline, but a much lower achievement of treatment targets in patients on antihypertensive pharmacotherapy (29.6% in men; 43.9% in women) \[[@CR31]\]. The highest prevalence of hypertension was found in *CARLA* (the Cardiovascular Disease, Living and Ageing in Halle Study in East Germany) with 66.7% in men and 76.9% in women, which might be due to an overall older study population (mean age in women: 50.0 years; mean age in men: 61.3 years) \[[@CR32]\].

### Diabetes mellitus {#Sec20}

Within the *KORA study,* a similar self-reported low prevalence in diabetes of 5.6% compared to STAAB with 5.7% was found \[[@CR33]\]. *KORA* participants with DM type 2 diabetes showed comparable glycemic control with a trend for secular improvement from 60% in the year 2000 to 71% in the year 2014 \[[@CR34]\], respectively (overall medication control in STAAB: 66%). With respect to the increased CV risk in diabetics \[[@CR4]\], we assessed the control of other CV risk factors in this group: despite respective medication, we found elevated BP in 52.6% of diabetic STAAB participants and high LDL cholesterol levels in 21.1%, respectively. The *DIAB-CORE study* (The Diabetes Collaborative Research of Epidemiologic Studies), which assessed the prevalence and management of DM related to BP and lipid management, found higher values of uncontrolled or insufficiently treated hypertension (63.6%), and suboptimally controlled dyslipidemia in diabetic patients (42.5%) \[[@CR31]\]. A longitudinal study of the *DIAB-CORE* Consortium in 2015 shows still a large proportion of insufficient hypertension control in diabetics (55.0%) \[[@CR35]\].

### Dyslipidemia {#Sec21}

The prevalence of dyslipidemia (total cholesterol ≥190 mg/dl or medical diagnosis of dyslipidemia) in *DEGS1* was 65.1% (women 65.7%; men 64.5%), but more than half of the affected in both genders were unreported. In individuals with known dyslipidemia, only 30.8% were on lipid-lowering medication \[[@CR36]\]. In our study, prevalence of dyslipidemia (LDL cholesterol \>115 mg/dl) was slightly lower (57.6%), and fewer subjects received insufficient pharmacotherapy (37.3%). This might be due to differing definitions of dyslipidemia, or the result of increased efforts regarding CV risk factor control in Germany.

### Lifestyle factors {#Sec22}

Overweight was prevalent in more than half of the study population, which is in line with *DEGS1* Data reporting a BMI ≥25 kg/m^2^ in 53.0% of women and 67.1% of men \[[@CR37]\]. Higher values were found in physically inactive participants (defined as \<2.5 h/week of moderate intensity), which was reported more frequently in women (84.5%) than in men (74.6%) \[[@CR38]\]. We further found a substantially lower prevalence of current smokers compared to other surveys performed in Germany in 2010 \[[@CR38], [@CR39]\]. Concordantly, the *SHIP* study (Study of Health in Pomerania) \[[@CR27]\] investigating long-term trends in lifestyle-related risk factors reported decreasing prevalence rates for tobacco smoking, overweight, and physical inactivity \[[@CR40]\] over time. However, despite promising signals, control of modifiable vascular risk factors in German remains high calling for concerted actions of better guideline implementation in primary prevention.

Determinants of cadiovasular risk factor control {#Sec23}
------------------------------------------------

In our study, accumulation of insufficiently controlled CV risk factors (i.e., three or more) was associated with male sex, higher age and lower level of education. Two settings became apparent: On the one hand side, there was a fairly large proportion of individuals unaware of or not reporting their risk factors in a structured, physician-led interview. Thus, one strategy for achieving better implementation of guidelines could be a more comprehensive screening for CV risk factors in the general population. On the other hand side, we observed a high prevalence of individuals on pharmacotherapy for a CV risk factor ot achieving recommended treatment goals. As a consequence, education of physicians treating towards targets remains tiring but ever so important effort.

There might be a difference in BP assessed by mercury manometers in primary care practices compared to oscillometric techniques used in our study, which could have resulted in lower mean values for systolic and diastolic BP \[[@CR41]\]. This would be in line with findings from the *HYDRA* study (Hypertension and Diabetes Risk Screening and Awareness Study), which reported on an insufficient BP control that seemed to be unnoticed by the treating physicians \[[@CR9]\]. Another issue might be the mismatch of insufficient knowledge and compliance from patients´ side and the lack of time for a comprehensive evaluation of all guidelines applying for an individual patient combined with explanations and close guidance from physicians´ side \[[@CR42], [@CR43]\].

The *LifeLines cohort study* \[[@CR44]\] from the Netherlands focused on the use of lipid-lowering drugs in 70,292 participants (mean age 45 years; *n* = 68,954 without CVD and stroke) based on adherence to the national guidelines for CVD prevention \[[@CR45]\]. This study found inadequate control in 77% of the 3268 individuals eligible for lipid-lowering medication. In the entire cohort, prevalence of hypertension (19.0%) and DM (1.7%) was comparatively low, while 22% were current smokers \[[@CR44]\]. Another study from the Netherlands (*n* = 1,203,290) revealed a rising number of individuals on CV pharmacotherapy with increasing age \[[@CR46]\]. In our sample, we observed 422 (30.7%) participants receiving CV pharmacotherapy increasing from 3% in the age group 30--39 years up to 73.5% in the oldest age group 70--79 years. Interestingly, highest frequencies for of unreported high BP (76.5%) and high LDL cholesterol (78.0%) were found at the age group 30--39 years, and for HbA1c \>6.5% (43.5%) at the age group 60--69 years. Of those at high CVD risk, 36 (48.6%) had unreported LDL cholesterol levels ≥100 mg/dl. The importance of this finding is illustrated by a recent study determining the characteristics of culprit plaque in young patients who experienced an acute coronary syndrome. There, patients aged \<35 years showed a significant higher risk of plaque rupture \[[@CR47]\].

Risk factor control in primary care settings across Europe {#Sec24}
----------------------------------------------------------

Large patient cohort studies from primary care settings like *DETECT* (Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment \[*n* = 55,518; mean age 53.9 years, 59.3% women\]), *HYDRA* (*n* = 45,125; mean age 52.4 years) or *CoRiMa* (The German Coronary Risk Management \[*n* = 248,096, mean age 56.5 years, 53.0% women\]) in Germany reported prevalences ranging from 33% to 55% for hypertension, 30% to 62% for hyperlipidemia, and 14 to 29% for diabetes \[[@CR9]--[@CR11], [@CR14]\]. Due to different thresholds, the reported prevalence of CV risk factors in previous studies varied substantially: e.g., thresholds for HbA1c in *DETECT* were \>6.1% and in CoRiMa ≥6.5%; hyperlipidemia in CoRiMa (prevalence 62.0%) was based on LDL-C depends on individual cardiovascular risk and the number of risk factors, whereas *DETECT* (prevalence 29.1%) used a threshold of LDL cholesterol \>115 mg/dl. As expected, achievement of treatment goals heavily depends on these definitions and are therefore difficult to compare. Treatment goals were achieved in *CoRiMa* for LDL cholesterol in 29%, for BP in 28%, for HbA1c ≥6.5% and/or use of antidiabetic medication in 36%. *HYDRA*, by contrast reported a considerably lower proportion of adequate medication control in only 19% of hypertensive patients taking into account that blood pressure was not standardized an measured in routine care, which may lead into an overestimation of hypertension (white-coat hypertension) \[[@CR9]\].

The *EURIKA study* \[[@CR15]\] (European Study on CVD Risk Prevention and Management in Daily Practice \[conducted in 12 European countries\]) and *EUROASPIRE IV* \[[@CR48]\] (European Action on Secondary and Primary Prevention by Intervention to Reduce Events \[conducted in 14 European countries\]) reported on inadequate medication control in 59% to 61% of hypertensives, 27% to 67% of patients with dyslipidemia, and in 41% (*EUROASPIRE*, HbA1c \<7%) to 63% (*EURIKA*, HbA1c ≥6.5%) of diabetics across Europe. An observational study of 8928 patients from 320 general practices over 10 European countries assessed predictors for risk factor control in patients at high vascular risk. Predictors for poor risk factor control were female sex, living alone, and lower educational status \[[@CR2]\].

Risk factor control by absolute risk for fatal CVD {#Sec25}
--------------------------------------------------

Applying SCORE, 35.6% of the participants were at medium and 7.5% at high to very high risk for CV death within the upcoming 10 years, probably mainly due to the age distribution of our population. Vascular risk factor control was worst amongst participants at highest risk of subsequent CVD. There are a few further patient cohort studies available which calculated the cardiovascular disease risk via SCORE. The German *EURIKA* study assessed the 10-year risk of CVD death in 7641 outpatients free from CVD aged ≥50 years (low vs. high CVD risk) and found a quite higher percentage of individuals at high risk (40.1%). With 22%, also higher proportions for participants at high risk was reported for the CoRiMa study compared to STAAB. In the *EURIKA* study about one-third of participants on pharmacotherapy was still at high CV risk \[[@CR11], [@CR15], [@CR42]\], implying insufficient risk factor control. A Belgian survey conducted in primary care (*n* = 11,069) detected 38.0% individuals at high and 26.6% at very high risk \[[@CR49]\].

The comparatively low number of individuals at high to very high risk in our population-based study (7.5%) indicates that the prevalence of subjects at high risk for CV death might be overestimated in studies including primary care patients because of different risk profiles such as a higher comorbidity burden in a sicker and older population. Further, CV risk factor detection might be much higher when there is a clinical suspicion of risk.

Limitations {#Sec26}
-----------

Owing to the study design and recruitment methodology, several limitations apply. We cannot exclude effects of selection bias, as only 32.6% of the invited population participated in the study. More healthy subjects might have had a higher motivation to participate in the STAAB program. Findings from our local Würzburg population may not be generalizable to other regions in Germany due to regional differences in age structure, risk factor profile, or lifestyle factor distribution. Due to the limited availability of original data from other studies, we were unable to provide direct age-standardized comparisons. We further did not assess, whether respective lifestyle advice had been given by the participants´ healthcare provider. Moreover we have no information about potential inflammation markers. Despite standardized measurements, single-occasion measurements (e.g., BP levels) may have led to amplified associations. Furthermore, the predictive model only accounted for measured factors leaving room for residual confounding.

Conclusion {#Sec27}
==========

Our results derived from a German population-based sample indicate that there is considerable potential to improve adherence to CV prevention guidelines, particularly in the management of hypertension, DM, overweight, physical activity, and smoking. Considering the high values of unreported high BP and LDL cholesterol levels in younger age groups (30--39 years), a target for better guideline implementation might be a more comprehensive screening for vascular risk factors particularly in younger age groups of the general population. The association of age, male sex and educational level with a greater number of uncontrolled risk factors suggests that prevention strategies should also focus on individual patient needs considering specific explanations and close guidance from the physician's side, in particular for specific subgroups such as people with lower educational level.
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Additional file 1:**Table S1.** Definition of uncontrolled cardiovascular risk factors. Definition of the six uncontrolled cardiovascular risk factors (blood pressure, glycemic control, LDL cholesterol, tabaco abuse, physically inactive, overweight) and their subgroups (PDF 337kb) Additional file 2:**Table S2.** Sensitivity analysis according to sex. Odds ratios (OR) (95%-CI) for 3--6 (referent: 0--2) insufficiently controlled cardiovascular risk factors adjusted for sociodemographic status stratified by sex (PDF 343 kb)
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